Sharon Castellino is an Oncology physician affiliated with Emory University. OpenAlex indexes 394 publications with 5,537 citations (h-index 39); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5461 Meridian Mark Rd Ste 400
Atlanta, GA 303423283
Telephone
404-785-1112Registry record last updated 6 Jun 2022.
Clinical trials
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
Sponsor: National Cancer Institute (NCI)
- RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors
Sponsor: Wake Forest University Health Sciences
- Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2021–2025 per NIH RePORTER. The latest:
- Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma
Emory University
FY2025$178,909R50CA285492 - Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma
Emory University
FY2024$178,909R50CA285492 - Understanding the impact of the Affordable Care Act on cancer treatment and outcomes for adolescents and young adults (AYA)
Emory University
FY2022$71,820R03CA259665
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Journal of Clinical Oncology
2025 - Personalized Impression Generation for PET Reports Using Large Language Models
Journal of Digital Imaging
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”